Potential benefit of dolutegravir once daily: Efficacy and safety

HIV/AIDS - Research and Palliative Care

Volumn 5, Issue , 2013, Pages 29-40

  Fantauzzi, Alessandra ^a   Turriziani, Ombretta ^b   Mezzaroma, Ivano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antiretroviral drugs; Dolutegravir; HIV 1 integrase; Integrase inhibitors; Once daily

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTACID AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; COBICISTAT; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; ENFUVIRTIDE; LIPID; LIVER ENZYME; LOPINAVIR; MARAVIROC; MODAFINIL; MULTIVITAMIN; NEVIRAPINE; PHENOBARBITAL; PHENYTOIN; PIOGLITAZONE; PLACEBO; PROTON PUMP INHIBITOR; RALTEGRAVIR; RIFABUTIN; RIFAMPICIN; RITONAVIR; STAVUDINE; TRIACYLGLYCEROL LIPASE; TROGLITAZONE; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; APHASIA; AREA UNDER THE CURVE; CONCENTRATION RESPONSE; CONVULSION; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DIZZINESS; DREAM; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOOD; FOOD DRUG INTERACTION; HEART ARRHYTHMIA; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; INSOMNIA; LARYNX PAIN; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SORE THROAT; UPPER RESPIRATORY TRACT INFECTION; VIRUS RESISTANCE;

EID: 84873636880     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/HIV.S27765     Document Type: Review

References (64)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-860.
2. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293-299.
3. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F. ATHENA national observational cohort study. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010;24(10):1527-1535.
4. Juday T, Gupta S, Grimm K, Wagner S, Kim E. Factors associated with complete adherence to HIV combination antiretroviral therapy. HIV Clin Trials. 2011;12(2):71-78.
5. Ammassari A, Trotta MP, Shalev N, Marconi P, Antinori A. Beyond virological suppression: the role of adherence in the late HAART era. Antivir Ther. 2012;17(5):785-792.
6. Broder S, Fauci AS. Progress in drug therapies for HIV infection. Public Health Rep. 1988;103(3):224-229.
7. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287(5453):646-650.
8. Reinke R, Lee DJ, Robinson WE. Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo acid. Antimicrob Agents Chemother. 2002;46(10):3301-3303.
9. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov. 2005;4(3):236-248.
10. [No authors listed]. FDA approves raltegravir for HIV-1 treatment naïve patients. AIDS Alert. 2009;24:(9):106-107.
11. Markowitz M, Nguyen BY, Gotuzzo E, et al. Protocol 004Part II Study Team. Rapid and durable antiretroviral effect of the HIV-1integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46(2):125-133.
12. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369(9569):1261-1269.
13. Eron JJ, Rockstroh JK, Reynes J, et al. QDMRK Investigators. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non inferiority trial. Lancet Infect Dis. 2011;11(12):907-915.
14. Cooper DA, Steigbigel RT, Gatell JM, et al. BENCHMARK Study Teams. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359(4):355-365.
15. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMARK 1 and 2 Phase III trials. Clin Infect Dis. 2010;50(4):605-612.
16. DeJesus E, Berger D, Markowitz M, et al. 183-001 Study Team. Antiviral activity, pharmacokinetics, and dose response of the HIV-1integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr. 2006;43(1):1-5.
17. Klibanov OM. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr Opin Investig Drugs. 2009;10(2):190-200.
18. Zolopa AR, Berger DS, Lampiris H, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis. 2010;201(6):814-822.
19. Schrijvers R, Debyser Z. Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF. Expert Opin Pharmacother. 2012;13(13): 1969-1983.
20. Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet. 2011;50(4):229-244.
21. Hu Z, Kuritzkes DR. Effect of raltegravir resistance mutations in HIV-1integrase on viral fitness. J Acquir Immune Defic Syndr. 2010; 55(2):148-155.
22. Goethals O, Clayton R, Van Ginderen M, et al. Resistance mutations in human immunodeficiency virus type 1integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol. 2008;82(21):10366-10374.
23. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Dec 2010. Top HIV Med. 2010;18(5): 156-163.
24. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis. 2011;203(9):1204-1214.
25. Quashie PK, Sloan RD, Wainberg MA. Novel therapeutic strategies targeting HIV integrase. BMC Med. 2012;10:34.
26. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55(2):813-821.
27. Eron J, Livrozet JM, Morlat P, et al. Activity of integrase inhibitor S/GSK9572in subjects with HIV exhibiting raltegravir resistance: week 24 results of VIKING Study. J Int AIDS Soc. 2010;13 Suppl 4:O51.
28. Yoshinaga Y, Kanamori-Koyama M, Seki T, et al. Strong inhibition of wild-type and integrase inhibitor (INI)-resistant HIV integrase (IN) strand transfer reaction by the novel INI S/GSK1349572. International HIV and Hepatitis Virus Drug Resistance Workshop. Dubrovnik, Croatia, June 8-12, 2010. Available from: http://www.natap.org/2010/ResisWksp/ResisWksp_31.htm.
29. Katlama C, Murphy R. Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs. 2012;21(4):523-530.
30. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):254-258.
31. Bar-Magen T, Sloan RD, Faltenbacher VH, et al. Comparative biochemical analysis of HIV-1subtype B and C integrase enzymes. Retrovirology. 2009;6:103.
32. Sloan RD, Wainberg MA. The role of unintegrated DNA in HIV infection. Retrovirology. 2011;8:52.
33. Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 2012;56(3):1627-1629.
34. Chen S, Min SS, Peppercorn A, et al. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization. Pharmacotherapy. 2012;32(4):333-339.
35. Koteff J, Borland J, Chen S, et al. An open label, placebo-controlled study to evaluate the effect of dolutegravir (DTG/GSK 1349572) on iohexol and para-aminohippurate clearance in healthy subjects. Abstract A1-1728 presented at the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-29, 2011.
36. Song I, Borland J, Chen S, et al. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br J Clin Pharmacol. 2011;72(1):103-108.
37. Song I, Min SS, Borland J, et al. The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J Clin Pharmacol. 2011;51(2):237-242.
38. Song I, Borland J, Chen S, Peppercorn A, Wajima T, Piscitelli SC. Effect of fosamprenavir/ritonavir on the pharmacokinetics of the integrase inhibitor, dolutegravir, in healthy subjects. Abstract 1727 presented at the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-29, 2011.
39. Song I, Min SS, Borland J, et al. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J Acquir Immune Defic Syndr. 2010;55(3):365-367.
40. Song I, Borland J, Min S, et al. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother. 2011;55(7):3517-3521.
41. Ford SL, Gould E, Chen S, et al. Lack of pharmacokinetic (PK) interaction between rilpivirine and the integrase inhibitors dolutegravir and S/GSK1265744. Abstract A-1249 presented at the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012.
42. Patel P, Song I, Borland J, et al. Evaluation of antiacid and multivitamin effects on S/GSK1349572 pharmacokinetics in healthy volunteers. J Antimicrob Chemother. 2011;66(7):1567-1572.
43. Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011;25(14):1737-1745.
44. Rockstroh J, Felizarta F, Maggiolo F, et al. Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276). J Int AIDS Soc. 2010;13 Suppl 4:O50.
45. van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111-118.
46. Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir in combination therapy exhibits rapid and sustained antiviral response in ARV-naïve adults: 96-week results from SPRING-1 (ING112276). Abstract 102LB presented at the Nineteenth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, March 5-8, 2012.
47. Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir (DTG; S/GSK1349572) is non-inferior to raltegravir (RAL) in antiretroviral-naive adults: 48-week results from SPRING-2 (ING113086). Abstract THLBB04 presented at the Nineteenth International AIDS Conference, Washington, DC, July 22-27, 2012.
48. Walmsley S, Antela A, Clumeck N, et al. Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results-SINGLE (ING114467). Abstract H-556b presented at the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012.
49. Eron J, Durant J, Poizot-Martin I, et al. Activity of next generation integrase inhibitor (INI) S/GSK1349572in subjects with HIV exhibiting raltegravir resistance: initial results of VIKING study (ING112961). Abstract MOAB0105 presented at the Eighteenth International AIDS Conference, Vienna, Austria, July 18-23, 2010.
50. Eron J, Kumar P, Lazzarin A, et al. DTG in subjects with HIV exhibiting RAL resistance: functional monotherapy results of VIKING study cohort II. Abstract 151LB presented at the Eighteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 27-March 2, 2011.
51. Eron J, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir (DTG) in HIV-1 treatment-experienced subjects with raltegravir-resistant virus: 24-week results of the VIKING Study. J Infect Dis. December 7, 2012. [Epub ahead of print.]
52. Nichols G, Mills A, Grossberg R, et al. Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3. Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection. J Int AIDS Soc. 2012;15 Suppl 4:18112.
53. Mouscadet JF, Delelis O, Marcelin AG, Tchertanov L. Resistance to HIV-1integrase inhibitors: a structural perspective. Drug Resist Updat. 2010;13(4-5):139-150.
54. Métifiot M, Vandegraaff N, Maddali K, et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS. 2011;25(9):1175-1178.
55. Van Wesenbeeck L, Rondelez E, Feyaerts M, et al. Cross-resistance profile determination of two second-generation HIV-1integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrob Agents Chemother. 2011;55(1):321-325.
56. Seki T, Kobayashi M, Wakasa-Morimoto C, et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60integrase mutant molecular clones. Abstract 555 presented at the Seventeenth Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 16-19, 2010.
57. Vavro C, Underwood M, Madsen H, et al. Polymorphisms at position 101 and 124in the HIV-1integrase gene: lack of effects on susceptibility to S/GSK1349572. Abstract H-935 presented at the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010.
58. Quashie PK, Mesplède T, Han YS, et al. Characterization of the R263K mutation in HIV-1integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol. 2012;86(5):2696-2705.
59. Mesplede T, Quashie P, Oliveira M, et al. Selection in culture of HIV resistance to dolutegravir by mutations at integrase positions R263K and H51Y that diminish viral replication fitness. Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection. J Int AIDS Soc. 2012;15 Suppl 4:18113.
60. Hightower KE, Wang R, Deanda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1integrase-DNA complexes. Antimicrob Agents Chemother. 2011;55(10):4552-4559.
61. Saladini F, Meini G, Bianco C, etal; for the ARCA Collaborative Group. Prevalence of HIV-1integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients. Clin Microbiol Infect. 2012;18(10):E428-E430.
62. Soriano V, Cox J, Eron JJ, et al. Dolutegravir (DTG, S/GSK1349572) treatment of HIV suppression at week 24in the VIKING study. Abstract PS1/2 presented at the Thirteenth European AIDS Conference, Belgrade, Serbia, October 12-15, 2011.
63. Underwood MR, Johns BA, Sato A, Martin JN, Deeks SG, Fujiwara T. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr. 2012;61(3):297-301.
64. Waki K, Sugawara Y. Implications of integrase inhibitors for HIV-infected transplantation recipients: raltegravir and dolutegravir (S/GSK 1349572). Biosci Trends. 2011;5(5):189-191.